A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

Advanced Parkinson's Disease Clinical Trial

Official title:

An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01723904
• Other study ID #: PD0015
• Status: Completed
• Phase: Phase 3
• First received: November 6, 2012
• Last updated: May 7, 2014
• Start date: October 2012
• Est. completion date: April 2013

Study information

• Verified date: May 2014
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Ministry of Food and Drug SafetyMalaysia: Ministry of HealthTaiwan : Food and Drug AdministrationAustralia: Department of Health and Ageing Therapeutic Goods AdministrationSingapore: Health Sciences Authority
• Study type: Interventional

Clinical Trial Summary

This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: April 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject is male or female, aged = 30 and < 80 years at informed consent

• Subject has idiopathic Parkinson's Disease, of more than 3 years duration, as defined by the cardinal sign, bradykinesia, and the presence of at least 1 of the following: resting tremor, rigidity, impairment of postural reflexes, and without any known or suspected cause of Parkinsonism

• Subject has motor fluctuations such as wearing, dyskinesia

• Subject has experienced nocturias for at least 3 nights within 7 days prior to Baseline

• Subject is taking levodopa (L-DOPA, immediate and/or controlled release) in combination with benserazide or carbidopa and has been on a stable dose of L-DOPA for at least 28 days prior to Baseline (Visit 2)

• Subject is taking a non-ergot dopamine agonist (pramipexole = 1.5 mg/day or ropinirole = 6.0 mg/day) and has been on a stable dose of non-ergot dopamine agonist for at least 28 days prior to Baseline (Visit 2)

Exclusion Criteria:

• Subject is receiving therapy with tolcapone or budipine

• Subject is receiving therapy with one of the following drugs either concurrently or within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, quetiapine), monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or amphetamine

• Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension within the 6 months prior to Baseline (Visit 2)

• Subject has a known hypersensitivity to any components of the study medication, such as a history of significant skin hypersensitivity to adhesives, known hypersensitivity to other transdermal medications, or has unresolved contact dermatitis

• Subject is pregnant or nursing, or is of child-bearing potential (ie, is (i) not surgically sterile, or, (ii) not using adequate birth control methods [including at least one barrier method] or, (iii) not sexually abstinent, or (iv) not at least 2 years post menopausal)

• Subject had a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs syndrome, or periodic limb movement disorder

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Advanced Parkinson's Disease
• Parkinson Disease

Intervention

Drug:
• Rotigotine
Application of Rotigotine up to 8 mg/24 h patches for 24 hours.

Locations

Country	Name	City	State
Australia	402	Chatswood	New South Wales
Australia	403	Melbourne	Victoria
Australia	401	Sydney	New South Wales
Korea, Republic of	104	Busan
Korea, Republic of	112	Busan
Korea, Republic of	109	Daegu
Korea, Republic of	111	Gyeonggi-Do
Korea, Republic of	101	Seoul
Korea, Republic of	102	Seoul
Korea, Republic of	103	Seoul
Korea, Republic of	105	Seoul
Korea, Republic of	107	Seoul
Korea, Republic of	108	Seoul
Korea, Republic of	110	Seoul
Malaysia	202	Kuala Terengganu
Malaysia	204	Kuching Sarawak
Malaysia	201	Pulau Pinang
Singapore	501	Singapore
Singapore	502	Singapore
Taiwan	302	Taichung
Taiwan	303	Tainan
Taiwan	306	Taipei

Sponsors (2)

Lead Sponsor	Collaborator
UCB BIOSCIENCES GmbH	Otsuka Pharmaceutical Co., Ltd.

Countries where clinical trial is conducted

Australia,  Korea, Republic of,  Malaysia,  Singapore,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period	The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable; = No side effects; = Side effects do not significantly interfere with subject's functioning; = Side effects significantly interfere with the subject's functioning; = Side effects outweigh therapeutic efficacy.	Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)	No
Primary	Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III ("on" State) Total Score	The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108.; A negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.	From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)	No
Primary	Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of "on" and "Off" State) Total Score	UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible).; UPDRS Part II total score (average of "on" and "off" state) is the average of UPDRS Part II total score ("on" state) and Part II total score ("off" state).; A negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.	From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)	No
Primary	Change From Baseline to the End of the Treatment Period in Absolute Time Spent "Off"	Absolute time spent "off" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent "off" decreased from Baseline and therefore indicates an improvement from Baseline.; Only subjects with time spent "off" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.	From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)	No
Secondary	Change From Baseline to the End of the Treatment Period in Time Spent "on" Without Troublesome Dyskinesia	Absolute time spent "on" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent "on" without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.	From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)	No
Secondary	Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score	The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions.; A negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.	From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)	No
Secondary	Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score	The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality.; A negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.	From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)	No

External Links

•   FDA Safety Alerts and Recalls
•   Product Information